[Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 6 to 11 years, F508del mutation, gating mutation, heterozygous) - Benefit assessment according to ยง35a Social Code Book V]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004105
Original Title: Ivacaftor/Tezacaftor/Elexacaftor und Ivacaftor (zystische Fibrose, 6 bis 11 Jahre, F508del-Mutation, GatingMutation, heterozygot)
Project Status: Completed
Year Published: 2022
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Cystic Fibrosis
  • Child
  • Drug Therapy, Combination
  • Ivacaftor
  • Tezacaftor
  • Elexacaftor
  • Cystic fibrosis
  • Child
  • Benefit Assessment
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.